Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James E Hilbert

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
The Journal of Pediatrics|March 20, 2013
New insights about the incidence, multisystem manifestations, and care of patients with congenital myotonic dystrophyJames E Hilbert, Nicholas E Johnson, Richard T Moxley
Neurology|April 25, 2018
Author response: High frequency of gastrointestinal manifestations in myotonic dystrophy type 1 and type 2James E Hilbert, Charles A Thornton, Richard T Moxley
Journal of Medicinal Chemistry|April 2, 2004
2-aminothiazole-derived opioids. Bioisosteric replacement of phenolsAo Zhang, Wennan Xiong, James E Hilbert, et al.
Cancer Causes & Control : CCC|July 31, 2009
Hypothesis: neoplasms in myotonic dystrophyChristine M Mueller, James E Hilbert, William Martens, et al.
Journal of Medicinal Chemistry|December 30, 2003
10-Ketomorphinan and 3-substituted-3-desoxymorphinan analogues as mixed kappa and micro opioid ligands: synthesis and biological evaluation of their binding affinity at opioid receptorsAo Zhang, Wennan Xiong, Jean M Bidlack, et al.
Journal of Neurology|May 24, 2012
Correlates of tumor development in patients with myotonic dystrophyMaya Das, Richard T Moxley, James E Hilbert, et al.
Journal of Neurology|October 14, 2016
Medication adherence in patients with myotonic dystrophy and facioscapulohumeral muscular dystrophyBryan P Fitzgerald, Kelly M Conn, Joanne Smith, et al.
Plos One|November 16, 2013
Quantifying cancer absolute risk and cancer mortality in the presence of competing events after a myotonic dystrophy diagnosisShahinaz M Gadalla, Ruth M Pfeiffer, Sigurdur Y Kristinsson, et al.
Muscle & Nerve|July 2, 2022
Milestones of progression in myotonic dystrophy type 1 and type 2Johanna I Hamel, Michael P McDermott, James E Hilbert, et al.
Journal of Medicinal Chemistry|November 14, 2003
Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptorsJohn L Neumeyer, Ao Zhang, Wennan Xiong, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
The Journal of Pediatrics|March 20, 2013
New insights about the incidence, multisystem manifestations, and care of patients with congenital myotonic dystrophyJames E Hilbert, Nicholas E Johnson, Richard T Moxley
Neurology|April 25, 2018
Author response: High frequency of gastrointestinal manifestations in myotonic dystrophy type 1 and type 2James E Hilbert, Charles A Thornton, Richard T Moxley
Journal of Medicinal Chemistry|April 2, 2004
2-aminothiazole-derived opioids. Bioisosteric replacement of phenolsAo Zhang, Wennan Xiong, James E Hilbert, et al.
Cancer Causes & Control : CCC|July 31, 2009
Hypothesis: neoplasms in myotonic dystrophyChristine M Mueller, James E Hilbert, William Martens, et al.
Journal of Medicinal Chemistry|December 30, 2003
10-Ketomorphinan and 3-substituted-3-desoxymorphinan analogues as mixed kappa and micro opioid ligands: synthesis and biological evaluation of their binding affinity at opioid receptorsAo Zhang, Wennan Xiong, Jean M Bidlack, et al.
Journal of Neurology|May 24, 2012
Correlates of tumor development in patients with myotonic dystrophyMaya Das, Richard T Moxley, James E Hilbert, et al.
Journal of Neurology|October 14, 2016
Medication adherence in patients with myotonic dystrophy and facioscapulohumeral muscular dystrophyBryan P Fitzgerald, Kelly M Conn, Joanne Smith, et al.
Plos One|November 16, 2013
Quantifying cancer absolute risk and cancer mortality in the presence of competing events after a myotonic dystrophy diagnosisShahinaz M Gadalla, Ruth M Pfeiffer, Sigurdur Y Kristinsson, et al.
Muscle & Nerve|July 2, 2022
Milestones of progression in myotonic dystrophy type 1 and type 2Johanna I Hamel, Michael P McDermott, James E Hilbert, et al.
Journal of Medicinal Chemistry|November 14, 2003
Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptorsJohn L Neumeyer, Ao Zhang, Wennan Xiong, et al.
Pageof 3